Population Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with Schizophrenia
Preprint
- 30 October 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Brexpiprazole, widely approved for the treatment of schizophrenia, is an atypical antipsychotic that modulates serotonin–dopamine activity. To better understand the pharmacokinetics (PK) of brexpiprazole in Japanese patients, a population PK model was constructed and used to estimate steady state PK profiles and parameters as well as dopamine D2/D3 receptor occupancy profiles after repeated oral administrations of brexpiprazole at 1 and 2 mg/day. Nonlinear mixed effects modelling was used to analyse data from a total of 398 healthy subjects and patients with schizophrenia who received brexpiprazole in three Japanese clinical trials. The PK of brexpiprazole were well described by a two-compartment disposition model with transit absorption compartments. Estimated glomerular filtration rate, age and cytochrome P450 2D6 phenotype were identified as significant covariates on CL/F only. The model predicted that, at a dose of 2 mg/day, trough plasma concentration (90% prediction interval) of brexpiprazole is 77.1 (22.4–173) ng/mL and that dopamine D2/D3 receptor occupancy is > 80% over one day for most patients at steady state. This suggests the recommended maintenance dose of 2 mg/day of brexpiprazole leads to clinically useful dopamine D2/D3 receptor occupancy at steady state in Japanese patients.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With SchizophreniaThe Journal of Clinical Pharmacology, 2023
- Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019Molecular Psychiatry, 2023
- An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participantsEuropean Journal of Clinical Pharmacology, 2020
- Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017Epidemiology and Psychiatric Sciences, 2020
- Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016Schizophrenia Bulletin, 2018
- Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With SchizophreniaThe Journal of Clinical Pharmacology, 2017
- Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled StudyInternational Journal of Neuropsychopharmacology, 2016
- SchizophreniaThe Lancet, 2016
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophrenia Research, 2015
- A reduction in between subject variability is not mandatory for selecting a new covariateJournal of Pharmacokinetics and Pharmacodynamics, 2012